Iktos Secures EIC Grant to Enhance AI Drug Discovery Platform

Iktos, a leader in AI-driven drug discovery, has secured a €2.5 million grant from the European Innovation Council (EIC) Accelerator to enhance its AI and robotics synthesis automation technology, announced in a press release. This funding could potentially increase by an additional €5 million, supporting Iktos' mission to revolutionize drug design by integrating AI-driven molecular generation, automated synthesis, and high-precision biological testing.

Over the next two years, Iktos plans to expand its drug discovery platform, building on its 2024 acquisition of Synsight and its proprietary technology, MTBench. This technology enables high-precision biological screening of challenging targets in biologically relevant environments. The investment will enhance Iktos' capabilities by integrating AI-driven molecular design, robotic synthesis, and biological testing, with each stage of the DMTA (design-make-test-analyze) cycle orchestrated by AI.

The EIC Accelerator's recognition underscores Iktos' pioneering work in AI for drug discovery. The platform aligns with the EIC Accelerator Challenge, "Human-Centric Generative AI Made in Europe," advancing AI in drug discovery while prioritizing transparency, strategic autonomy, and ethical standards. Iktos' approach ensures AI-generated molecules are both theoretically promising and synthetically viable, leveraging virtual synthesis and high-quality datasets validated by expert oversight.